Outlook Therapeutics, Inc. OTLK
0.64
(0.02)
(3.03%)
as of 25 Sep
- Market cap
- $159.5M
- P/E
- 0.0×
Follow OTLK
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.70 | 15.70 | 51.59 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.98) | (6.37) | (2.20) | (10.35) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
10.09 | 23.69 | 109.30 | (202.43) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.53) | (2.57) | (0.77) | (4.19) | |
EV/FCF |
(1.51) | (2.55) | (0.77) | (4.16) | |
Quick Ratio |
0.21 | 0.18 | 0.27 | 0.45 | |
Current Ratio |
0.38 | 0.35 | 0.54 | 0.81 | |
Net Debt/EBITDA |
(1.26) | (2.08) | (1.37) | (0.65) | |
Debt/Assets |
161.14% | 201.00% | 123.19% | 69.61% | |
Debt/Equity |
(0.93) | (0.95) | (0.93) | (1.75) | |
Asset Turnover |
0.33 | 0.34 | 0.02 | (0.05) | |
Operating CF/Net income |
0.93 | 0.65 | 1.76 | 1.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
(6,512.85%) | (300.91%) | 3,532.57% | 37,368.97% | |
Selling, General and Administrative Expense of Revenue |
(11,250.00%) | (713.04%) | 7,460.44% | 86,790.80% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
(1,983.22%) | (72.96%) | 594.51% | 9,100.00% | |
Graham Net Nets |
(0.91) | (0.42) | (1.74) | (0.06) | |
Graham Number |
6.11 | 6.46 | 3.39 | 1.34 | |
Earnings Yield |
(169.27%) | (183.18%) | (687.76%) | (65.68%) | |
Free Cash Flow Yield |
(141.71%) | (59.12%) | (276.29%) | (26.03%) | |
Revenue per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Operating CF per Share |
(0.36) | (0.25) | (0.10) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.36) | (0.25) | (0.10) | (0.15) | |
Cash per Share |
0.23 | 0.14 | 0.09 | 0.08 | |
Shareholders Equity per Share |
(0.92) | (0.64) | (0.35) | (0.08) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.92) | (0.64) | (0.35) | (0.08) | |
Free Cash Flow |
(12.38) | (14.94) | (7.83) | (21.01) | |
Working Capital |
(28.43) | (31.89) | (17.98) | (5.51) | |
Net Current Asset Value |
(33.38) | (39.62) | (29.98) | (13.41) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
14,480.17% | 1,909.10% | (3,495.37%) | (233,555.17%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.49 | 0.33 | 1.38 | 1.70 | |
Average Payables |
9.08 | 9.76 | 10.70 | 8.53 | |
Average Inventory |
— | 3.28 | 3.47 | 4.59 | |
Average Assets |
23.70 | 17.62 | 20.48 | 24.29 | |
Average Common Equity |
(52.63) | (44.42) | (30.73) | (23.79) |
Columns are period end dates